Pre-Market Most Active for Jul 30, 2025 : REPL, SOFI, TSLL, NVO, OPEN, SRPT, MRVL, NIO, BBAI, VFC, FUBO, BABA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 30 2025
0mins
Source: NASDAQ.COM
Pre-Market Activity: The NASDAQ 100 Pre-Market Indicator is up 41.58 points, with significant trading volumes observed in stocks like Replimune Group (REPL) and SoFi Technologies (SOFI), showing mixed performance ahead of earnings reports for several companies.
Earnings Forecasts: Companies such as Novo Nordisk (NVO) and Sarepta Therapeutics (SRPT) are set to report earnings soon, with forecasts indicating potential increases in earnings per share compared to the previous year, while others like Opendoor Technologies (OPEN) anticipate a slight decline.
Analyst Views on REPL
Wall Street analysts forecast REPL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for REPL is 11.43 USD with a low forecast of 3.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 7.900
Low
3.00
Averages
11.43
High
18.00
Current: 7.900
Low
3.00
Averages
11.43
High
18.00
About REPL
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
